Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2022-06-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于调整股票期权行权价格及限制性股票授予/回购价格的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding adjustments to stock option exercise prices and restricted stock grant/repurchase prices. It details board and supervisory committee meetings, approvals, legal opinions, and the rationale for the adjustments. The content focuses on corporate governance and management decisions related to stock-based compensation plans. There are no financial statements, earnings data, or investor presentations. The document is not a full report but an announcement of a corporate action related to stock options and restricted stock. This fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-06-28 Chinese
第四届董事会第三十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board of directors meeting, including adjustments to stock option prices, stock repurchases, amendments to the company bylaws and governance rules, and the scheduling of a shareholders meeting. It includes voting results and references to filings on the stock exchange information disclosure website. The content focuses on board decisions and governance matters rather than financial results or reports. The document length is 4443 characters, which is relatively short and consistent with a meeting resolution announcement rather than a full report. There is no financial statement or detailed financial data presented. Therefore, this document fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2022-06-28 Chinese
信息披露管理制度（2022年6月）
Governance Information Classification · 95% confidence The document is titled as an "Information Disclosure Management System" for a company, detailing the rules and procedures for information disclosure, including references to various types of reports such as annual reports, interim reports, temporary reports, and other disclosures. It extensively discusses regulatory compliance, disclosure obligations, and the content and timing of different reports. However, it is not an actual financial report or a specific filing like an annual report or interim report itself. Instead, it is a governance or procedural document outlining how the company manages its information disclosure obligations. This aligns with the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document is lengthy and detailed, not a brief announcement or certification, so it is not RPA or RNS. Therefore, the best classification is CGR with high confidence.
2022-06-28 Chinese
关于修订《公司章程》及相关治理制度的公告
Governance Information Classification · 95% confidence The document is a detailed announcement regarding the revision of the company's Articles of Association and related governance systems. It includes extensive legal and regulatory references, specific amendments to the company's charter, and governance rules. The content focuses on corporate governance structure, shareholder rights, board responsibilities, and compliance with securities laws. There is no indication that this is a financial report, earnings release, or a meeting transcript. It is not a simple announcement of a report publication but a substantive governance-related document. Therefore, the document fits best under the category of Governance Information (CGR).
2022-06-28 Chinese
关于召开2022年第二次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2022 second extraordinary general meeting of shareholders for the company 健帆生物科技集团股份有限公司. It includes information about the meeting date, voting procedures (including online voting), agenda items, registration details, and proxy forms. The content focuses on the announcement and procedural details for the shareholders' meeting rather than the results of the meeting or any financial data. There is no financial report or earnings data included. The document is not a report itself but a formal notification to shareholders about the meeting and how to participate. Therefore, it fits the category of AGM Information (AGM-R). The document length is about 5480 characters, which is consistent with a detailed meeting notice rather than a brief announcement or a full report.
2022-06-28 Chinese
董事会战略委员会议事规则（2022年6月）
Governance Information Classification · 100% confidence The document is titled '健帆生物科技集团股份有限公司 董事会战略委员会议事规则' which translates to 'Rules of Procedure for the Board Strategy Committee of Jianfan Biotechnology Group Co., Ltd.' It details the composition, responsibilities, meeting procedures, and operational rules of the Board's Strategy Committee. There is no financial data, no report of financial results, no announcement of voting results, no executive changes, no legal proceedings, no capital changes, and no investor presentation. The document is a governance-related internal rules document concerning board committee operations. Therefore, it fits the category of Governance Information (CGR). The document length is 2761 characters, which is consistent with a detailed governance rules document rather than a brief announcement or a full annual report.
2022-06-28 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.